TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Bayley Scales of Infant Development-Second Edition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hospitalizations or ED Visits
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Patient preference for medication protocol
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Psychomotor recovery time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time taken to fulfil discharge criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence/absence of hypovolemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Level of dental anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Rate of success at first device selected
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Glucose response to the Oral Glucose Tolerance Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Insulin response to the Oral Glucose Tolerance Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Social Skills Improvement System Rating Scale
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Change in Problem Behavior Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Teacher-Student Conflict
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Weight of sputum expectorated
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tobacco cessation rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite Anatomic and Symptomatic Success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serious Device-Related and/or Procedure-Related Complications
Endpoint domain: Adverse events/effects
Primary endpoint: Pharmacodynamics (serum & tissue biological markers; CCR5 receptor occupancy)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frailty Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With at Least 1 Dose Limiting Toxicity (DLT)
Endpoint domain: Adverse events/effects
Primary endpoint: Clinical Dementia Rating-Sum of Boxes (CDR-SB)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: T-cell peptide-specific response to the vaccine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Detection of trastuzumab in tumor
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Tolerated Dose (MTD) for IT trastuzumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of needle pass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Proportion of BCS accessing a SCP
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Successful expansion of NK cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mean Worst Daily Itch Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Control of hematemesis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: change in patient's perception of disease severity
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: change in patient's habits/risk behavior
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Rate of complete symptom resolution
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in concentration of Osteocalcin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Child School Readiness
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Family Well-being
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Physical Activity Volume change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients with severe hepatic fibrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Scale of Monoyer at 5 meters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Area Under the Curve (AUC) for Lipemia (Triglycerides)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of completed caregiver self-reported surveys
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: long term anti telomerase specific memory responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Panoramic Mandibular Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Brain Regional Gray Matter Density
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: non-exercise activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cytokine/chemokine production
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Induction of interferon-responsive genes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in Central Retinal Thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Identification of unknown biomarkers of grain intake immediately after grain consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Identification of unknown biomarkers of grain intake a day after grain consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Identification of unknown biomarkers of grain intake 2 days after grain consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Trough Forced Expiratory Volume in One Second (FEV1) Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Gait Parameters - Composite Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: gross motor development
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Patient Outcomes
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Adverse Events of IMISC and treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Endometrial abv3-integrin expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total numbers of chest compression with correct depth
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Sustained Virologic Response Rate at 24 Weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Hepatitis C Virus-RNA Levels at Week 24 and Week 48
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: High level of depressive symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Time for rewiring SB
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of endocrine comorbidities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: VerifyNow P2Y12 (PRU)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Major adverse coronary or cerebral event
Endpoint domain: Adverse events/effects
Primary endpoint: Patient-wide SUVmax on 18F-FCH PET/CT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of Achieving the Target on Blood Intact Parathyroid Hormone Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Post-operative analgesia duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Feasibility of screening procedure for major depression
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Intolerance of Uncertainty (IIU)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Time to successful weaning
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Live Birth Rate per transfer
Endpoint domain: Mortality/survival
Primary endpoint: Clinical pregnancy per transfer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Gestational length
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Surgical complications during pregnancy
Endpoint domain: Adverse events/effects
Primary endpoint: Atazanavir Oral Clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of type of gallstones
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Percent of Maximal Voluntary Isometric Contraction (%MVIC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of Severe Toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Bayley-III cognitive score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Bayley-III motor score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Missed School Days
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: incidence of all types/grades of adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With Stabilized Transthyretin (TTR) Tetramer
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Participant Perception of Pain
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mean net change in ADAS-Cog score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Centre for Epidemiological Studies-Depression Scale (CES-D)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: NINCDS-CSN Vascular Cognitive Impairment Battery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Full Scale Intelligence Quotient (IQ) score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Duration of Time the Patient Was in the OR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Estimate of Blood Loss in Cubic Centimeter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Time to debridement of wound
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Relative bioavailability (BA) of enzalutamide formulations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of post partum hemorrhage > 500mL in 1 hour
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Incremental Recovery
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Percentage of Eligible and Contacted Patients Randomised
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Percentage of enteroscopy exit velocity overdrive
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in Willingness and Intentions to Use Alcohol
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Self-Reported Alcohol Use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Alcohol-Related Negative Consequences
Endpoint domain: Adverse events/effects
Primary endpoint: Number of leukemia relapses in the central nervous system
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Tubal patency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Changes from Baseline Scale for Ataxia Rating Assessment (SARA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dating violence perpetration
Endpoint domain: Adverse events/effects
Primary endpoint: Acceptability of Decision Aid
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Usability of Decision Aid
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Tear lipid layer thickness measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Brain uptake of [11C]dLop
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in fatty acid enrichment of intramyocellular signaling molecules
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Serious or Non-serious Adverse Event Classified as Peripheral Neuropathy
Endpoint domain: Adverse events/effects
Primary endpoint: Serious or Non-serious Adverse Drug Reaction Classified as Peripheral Neuropathy
Endpoint domain: Adverse events/effects
Primary endpoint: Serious or Non-serious Adverse Event Classified as Myelosuppression
Endpoint domain: Adverse events/effects
Primary endpoint: Serious or Non-serious Adverse Drug Reaction Classified as Myelosuppression
Endpoint domain: Adverse events/effects
Primary endpoint: Serious or Non-serious Adverse Event Classified as Lung Disorder
Endpoint domain: Adverse events/effects
Primary endpoint: Cerebral blood flow (CBF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Histopathologic tube anomalies
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of newly detected atrial fibrillation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Disease Control Rate (Cohort I)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Response Evaluation Criteria in Solid Tumors (RECIST) Response (Complete Response [CR] or Partial Response [PR] vs Not CR or PR) (Cohort I)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Disease Control Rate (Cohort II)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Reduction in AF burden
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Participants With Disease Control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Toxicity assessed by SAEs
Endpoint domain: Adverse events/effects
Primary endpoint: Retinal perivascular cuff width
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Alive Without Local-regional Failure
Endpoint domain: Mortality/survival
Primary endpoint: Maximum tolerated dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Patients' concerns post treatment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Behavior changes post treatment
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Change in Urinary Prostaglandin Metabolites (PGE-M)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Psychomotor Impairment (Driving)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain as Measured by the Visual-analog Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Freedom From Device Related Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in microbiota composition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: optimal primary cytoreduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of participants diagnosed with celiac disease
Endpoint domain: Mortality/survival
Primary endpoint: mutation profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Distress Tolerance (Mean Latency to Quit the PASAT-C)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Inhibitory Control (Mean D-prime on the Go/No-Go)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Exercise capacity (six-minute walk test)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Vertebral Event
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Time to Pain Progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy in the treatment of Osteoarthritis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Number of Study Subjects With Life-threatening Thromboembolic Complications
Endpoint domain: Mortality/survival
Primary endpoint: Number of Subjects With Hematoma Growth Among Spot Sign Positive Subjects at 24 Hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Delayed post polypectomy bleeding
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of sexually transmitted disease
Endpoint domain: Adverse events/effects
Primary endpoint: Resolution of Fecal Incontinence (Patient Reported Outcomes)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Resolution of Fecal Incontinence (Physical Exam)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Improved bone mass and bone quality
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Level of troponin in blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Level of BNP in blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Level of CPK in blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Self-reported shoulder pain
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Metabolic alkalosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Immune state comparison
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Survival of the sealants
Endpoint domain: Mortality/survival
Primary endpoint: Occurrence of an acute attack of porphyria after treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severely abnormal Psychomotor Development Index scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Child language skills
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Child communicative skills
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Child social-emotional skills
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Amplitudes of Acoustic Event Related Potentials
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Fetal Cell Recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Genetic Analysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mortality six months after emergency department visit
Endpoint domain: Mortality/survival
Primary endpoint: Proportion of looking at faces
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cocaine abstinence for three or more consecutive weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fabry Associated Clinical Events (FACEs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Subjects Achieving Complete Healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of headache attacks per week
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absolute neutrophil count (ANC) response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Cycloplegic spherical refraction change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient acceptance of Whole body MRA
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Occurrence of adverse events grade ≥ 3
Endpoint domain: Adverse events/effects
Primary endpoint: anesthesia-related death within 24 hours of anesthesia
Endpoint domain: Mortality/survival
Primary endpoint: cardiac arrest within 24 hours of anesthesia
Endpoint domain: Adverse events/effects
Primary endpoint: severe neurological complications after intraspinal anesthesia
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of folate in portal vein
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Severity of Acute Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence of death or one major complication
Endpoint domain: Mortality/survival
Primary endpoint: Effectiveness of COPD screening procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Vitamin B12 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Folic acid levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes